Skip to main content

Table 3 Perindopril and echocardiographic data

From: Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

  (+) anti- AT1-AR (n = 82) (−) anti- AT1-AR (n = 56)
Baseline One-year Baseline One-year
LVEDD (mm) 69.5 ± 0.6 58.0 ± 0.8*† 69.9 ± 0.9 61.0 ± 0.6*
LVEDD (mm) 56.2 ± 0.6 42.0 ± 0.7*† 55.7 ± 0.8 47.1 ± 1.0*
LVEF (%) 34.1 ± 0.6 49.6 ± 1.2*† 33.8 ± 0.9 44.3 ± 1.1*
  1. LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction.
  2. Both groups of patients showed significant improvement in response to perindopril therapy. Of note, the presence of (+) anti-AT1-AR group experienced more pronounced benefits than the (−) anti-AT1-AR group. Data were collected and analysed as described in the text. (*P < 0.01 vs. baseline and †P < 0.05 vs. (−) anti-AT1-AR).